Samrat Pharmachem MD, chairman, board of directors and AGM
BSE: 530125Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹288.10.
- Next results date: the board meets on 14 Nov 2026 to consider: quarterly results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹86 Cr3,210th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 1.3
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- −3.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- −2.7%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.16
- Volume, BSEVolume. Shares traded on the last trading day.
- 1,601
Samrat Pharmachem board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.
- Chairperson and managing directorLALIT DAMODAR MEHTA
- Company Secretary and Compliance OfficerNishant Kankaria
7 directors4 independent3 executive
- LALIT DAMODAR MEHTA · Chairperson and managing directorExecutive · joined Jun 1992 · 36 months as independent · 1 listed board · 1 committee seat
- RAJESH LALIT MEHTAExecutive · joined Apr 2008 · 36 months as independent · 1 listed board · 1 committee seat
- MEGH RAJESH MEHTAExecutive · joined Oct 2015 · 36 months as independent · 1 listed board · 1 committee seat
- MANISHKUMAR INDULAL PIPALIAIndependent · joined Jul 2024 · 60 months as independent · 1 listed board · 1 as independent · 6 committee seats, 1 as chair
- SACHIN SAMIR KOTHARYIndependent · joined Jul 2024 · 60 months as independent · 1 listed board · 1 as independent · 6 committee seats, 1 as chair
- MEGHA SANJAY JAINIndependent · joined Aug 2024 · 60 months as independent · 1 listed board · 1 as independent · 6 committee seats, 1 as chair
- PIYUSH GANGJI DHARODIndependent · joined Jul 2025 · 60 months as independent · 1 listed board · 1 as independent · 6 committee seats, 3 as chair
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
1 director who left
- Renu Piyush Dharod, left 30 Jun 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 26 Sep 20267 of 7 present4 independent · 42 days in between
- 14 Aug 20267 of 7 present4 independent · 29 days in between
- 15 Jul 20267 of 7 present4 independent
Audit Committee
Chair MANISHKUMAR INDULAL PIPALIA
SACHIN SAMIR KOTHARY, MEGHA SANJAY JAIN, PIYUSH GANGJI DHAROD
- 26 Sep 20264 of 4 present4 independent · 42 days in between
- 14 Aug 20264 of 4 present4 independent · 29 days in between
- 15 Jul 20264 of 4 present4 independent
Nomination and remuneration committee
Chair SACHIN SAMIR KOTHARY
MANISHKUMAR INDULAL PIPALIA, MEGHA SANJAY JAIN, PIYUSH GANGJI DHAROD
- 14 Aug 20264 of 4 present4 independent · 75 days in between
- 30 May 20264 of 4 present4 independent
Stakeholders Relationship Committee
Chair PIYUSH GANGJI DHAROD
MANISHKUMAR INDULAL PIPALIA, SACHIN SAMIR KOTHARY, MEGHA SANJAY JAIN
- 14 Aug 20264 of 4 present4 independent · 75 days in between
- 30 May 20264 of 4 present4 independent
Risk Management Committee
Chair PIYUSH GANGJI DHAROD
MANISHKUMAR INDULAL PIPALIA, SACHIN SAMIR KOTHARY, MEGHA SANJAY JAIN
- 14 Aug 20264 of 4 present4 independent · 75 days in between
- 30 May 20264 of 4 present4 independent
Corporate Social Responsibility Committee
Chair PIYUSH GANGJI DHAROD
LALIT DAMODAR MEHTA, RAJESH LALIT MEHTA, MEGH RAJESH MEHTA, MANISHKUMAR INDULAL PIPALIA, SACHIN SAMIR KOTHARY, MEGHA SANJAY JAIN
- 14 Aug 20267 of 7 present4 independent · 75 days in between
- 30 May 20267 of 7 present4 independent
Health, Safety & Sustainanbility Committee
Chair MEGHA SANJAY JAIN
MANISHKUMAR INDULAL PIPALIA, SACHIN SAMIR KOTHARY, PIYUSH GANGJI DHAROD
No meeting listed in the filing.
Health, Safety & Sustainability Committee
- 14 Aug 20264 of 4 present4 independent · 75 days in between
- 30 May 20264 of 4 present4 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Shah & Savla LLPPeer-review certificate valid to Apr 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Samrat Pharmachem AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Samrat Pharmachem dividend history
Annual general meeting, 23 Sep 2026
6,150 shareholders on the register on 16 Sep 2026; present: 10 promoters and 29 others; votes counted by AQUEEL MULLA / A. A. MULLA AND ASSOCIATES.The company's voting result (opens in a new tab)
- To receive, consider and adopt the Audited Standalone Financial Statements of the company for the year ended March 31, 2026, together with Directors' and Auditors' Reports thereon.Ordinary97.56% for2.44% against
Against: promoters 0.00% · institutions 0.00% · other public 96.40%
Turnout: all 46.40% · promoters 92.13% · institutions 0.00% · other public 2.46%
- To appoint a Director in place of Mr. Megh Mehta (DIN: 07287394), who retires by rotation and, being eligible, offers himself for re-appointment.OrdinaryPromoters have an interest in it97.56% for2.44% against
Against: promoters 0.00% · institutions 0.00% · other public 96.40%
Turnout: all 46.40% · promoters 92.13% · institutions 0.00% · other public 2.46%
- Appointment of Statutory AuditorOrdinary97.56% for2.44% against
Against: promoters 0.00% · institutions 0.00% · other public 96.40%
Turnout: all 46.40% · promoters 92.13% · institutions 0.00% · other public 2.46%
- Ratification of Cost Auditors remunerationOrdinary97.56% for2.44% against
Against: promoters 0.00% · institutions 0.00% · other public 96.40%
Turnout: all 46.40% · promoters 92.13% · institutions 0.00% · other public 2.46%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- No
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.